Detail akcie Physiomics Rg online

Business Summary: Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Physiomics Plc revenues increased 44% to L784K. Net loss decreased 32% to L415K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects UK segment loss decrease of 32% to L458K.